ClinicalTrials.gg
CompletedNCT05562362Updated Sep 30, 2022

Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

A Phase 1 interventional study of RE-021, sparsentan in Healthy Subjects, sponsored by Travere Therapeutics, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-30.

Sponsored by Travere Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 6 years ago, and no results have been posted to the registry.
  • Registered 2 years 2 months after the study started (first participant enrolled Jun 2020, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Glomerulosclerosis, Focal Segmental with a site in United Kingdom — 5 open to participants now, 6 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United Kingdom.

Enrollment
7th of 12
47 · median 57
Started
2020
with 1 other
Phase 1
2 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
3 of 13
Travere Therapeutics, Inc.

Among the 13 studies in Glomerulosclerosis, Focal Segmental with a site in United Kingdom, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 2 in phase 1, and was the 10th registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

5 of the 13 studies in Glomerulosclerosis, Focal Segmental with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Glomerulosclerosis, Focal Segmental with a site in United Kingdom, or all of them as a file.
02

Study summary

This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels. In each dose level, subjects will be administered a single dose in the fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess Pharmacokinetics (PK) following multiple dosing.

Read the detailed description

This is a single-center, open-label, randomized, single- and multiple-dose, 3-way sequential study at 3 dose levels in healthy subjects. For logistical purposes subjects will be admitted to the unit to be dosed in groups of approximately 16 or fewer. Subjects will be randomized into one of the three dose levels. Within each dose level, subjects will be administered a single dose in the fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess PK following multiple dosing.

Subjects will undergo preliminary screening procedures for the study at the screening visit (Day -28 to Day -2). Subjects will be admitted to the clinical unit on the evening prior to investigational medicinal product (IMP) administration (Day -1) and will remain on site until 72 h post-final dose. Subjects will receive a single dose of sparsentan in the fasted state on Period 1, Day 1 (Study day 1) and a single dose of sparsentan in the fed state (high-fat breakfast) on Period 2, Day 1 (Study day 8), followed by multiple doses of sparsentan in the fed state on Period 3, Day 1 to 14 (Study days 12 to 25). On PK sampling days for the multiple dose treatment period (Period 3, Days 7, and 14; Study days 18 and 25), subjects will consume a high-fat breakfast before dosing; on other days, a standard breakfast will be provided.

A follow-up phone call will take place 5 to 7 days post-final dose to ensure the ongoing wellbeing of the subjects.

03

Conditions studied

  • Healthy Subjects

Keywords

  • Focal Segmental Glomerulosclerosis (FSGS)
  • Immunoglobulin A Nephropathy (IgAN)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or healthy females of non-
  2. Between 18 and 55 years of age, inclusive, at time of signing
  3. (BMI) of 18.0 to 30.0 kg/m2 as measured at screening
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent
  6. Must agree to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
  2. Subjects who are or are immediate family members of a study site employee or a sponsor employee
  3. Subjects who have previously been enrolled (dosed) in this study; subjects who have previously received sparsentan
  4. Evidence current SARS-CoV-2 infection
  5. History of any drug or alcohol abuse in the past 2 years
  6. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)
  7. A confirmed positive alcohol breath test at screening or admission
  8. Current smokers and those who have smoked within the last 3 months
  9. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
  10. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 3 months
  11. Females of :

    • A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or is (had no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone [FSH] concentration ≥40 IU/L)
  12. Subjects who are pregnant or lactating and subjects with pregnant or lactating partners. All women must have a negative pregnancy test at admission
  13. Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator or delegate at screening
  14. abnormal clinical chemistry, hematology or urinalysis as judged by the investigator at screening
  15. Serum (ALT) > 1.5× at screening
  16. Serum potassium > upper limit of normal at screening
  17. Confirmed positive drugs of abuse test result at screening or admission to Period 1
  18. interval by Fridericia's formula (QTcF) greater than 450 msec; ventricular rate less than 40 per minute or greater than 90 per minute at screening or prior to dosing
  19. For supine vital signs: systolic blood pressure less than 100 mmHg or greater than 140 mmHg (in subjects > 45 years of age up to 160 mmHg is acceptable); diastolic blood pressure less than 60 mmHg or over 90 mmHg at screening and pre-first dose.
  20. Decrease in systolic blood pressure of 20 mmHg or more and/or decrease in diastolic blood pressure of 10 mmHg or more, measured after standing for approximately 2 to 5 min at screening and pre-dose in Period 1.
  21. Increase in heart rate of over 30 bpm measured after standing for 2 to 5 min at screening and pre-dose Period 1
  22. Any current or recent symptoms of postural hypotension or postural tachycardia at screening and pre-dose Period 1
  23. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
  24. Evidence of renal impairment at screening, as indicated by an of \<90 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) (2009) equation
  25. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
  26. Subjects with a history of cholecystectomy or gall stones
  27. Serious adverse reaction or serious to any drug or the formulation
  28. Subjects with a history of any hypersensitivity to angiotensin receptor blockers, endothelin receptor antagonists or the suspension formulation excipients
  29. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
  30. Donation or loss of greater than 400 mL of blood within the previous 3 months
  31. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than 4 g of paracetamol per day or hormone replacement therapy [HRT]) in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the PI
  32. Use of any medication, eg erythromycin, itraconazole, and gestodene, that is known to inhibit within 14 days before IMP administration
  33. Use of any medication or substance known to induce CYP3A4, eg St John's Wort, within 30 days before IMP administration
  34. Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Fasted State

    Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will be randomized to 1 of 3 dose levels (200mg, 400mg and 800 mg) and will receive a single dose of sparsentan in the fasted state on Period 1, Day 1 (Study Day 1)

    Drug: RE-021, sparsentan

  • Experimental
    Fed State

    Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have a single dose of sparsentan (200mg, 400mg and 800 mg) in the fed state (high-fat breakfast) on Period 2, Day 1 (Study Day 8)

    Drug: RE-021, sparsentan

  • Experimental
    Fed State - Multiple

    Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have multiple doses of sparsentan (200mg, 400mg and 800 mg) in the fed state on Period 3, Days 1 to 14 (Study days 12 to 25)

    Drug: RE-021, sparsentan

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted states - Cmax

    Evaluation of, at minimum, the maximum concentration (Cmax) parameters for sparsentan following a single dose of sparsentan as an oral suspension in the fed or fasted state.

    Time frame: Study Days 1 and 8

  2. Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted states - AUC(0-last)

    Evaluation of, at minimum, the area under the concentration-time curve from dosing time 0 (AUC(0-last)) parameters for sparsentan following a single dose of sparsentan as an oral suspension in the fed or fasted state.

    Time frame: Study Days 1 and 8

  3. Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted - states - AUC(0-inf)

    Evaluation of, at minimum, the area under the concentration curve to infinite (AUC(0-inf)) time parameters for sparsentan following a single dose of sparsentan as an oral suspension in the fed or fasted state.

    Time frame: Study Days 1 and 8

  4. Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat - breakfast - Cmax

    Evaluation of the ratio, fed/fasted, for the Cmax

    Time frame: Study Days 1 and 8

  5. Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat - breakfast - AUC(0-last)

    Evaluation of the ratio, fed/fasted, for the AUC(0-last)

    Time frame: Study Days 1 and 8

  6. Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat breakfast - AUC(0-inf)

    Evaluation of the ratio, fed/fasted, for the AUC(0-inf)

    Time frame: Study Days 1 and 8

  7. Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - Cmax

    Evaluation of, at minimum, the following pharmacokinetics parameters for sparsentan following multiple doses of sparsentan as an oral suspension in the fed state: Cmax from a single dose for Study days 18 and 25 (Period 3, Days 7 and 14)

    Time frame: Study Days 12 to 28

  8. Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - AUC(0-24)

    Evaluation of, at minimum, the following pharmacokinetics parameters for sparsentan following multiple doses of sparsentan as an oral suspension in the fed state: Area under the plasma concentration-time curve over the last 24-h dosing interval (AUC(0-24)) from a single dose for Study days 18 and 25 (Period 3, Days 7 and 14)

    Time frame: Study Days 12 to 28

  9. Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - TCP (AUC(0-24)/AUC(0-inf)

    Evaluation of, at minimum, the following pharmacokinetics parameters for sparsentan following multiple doses of sparsentan as an oral suspension in the fed state: temporal change parameter (TCP) (AUC(0-24)/AUC(0-inf)) from a single dose for Study days 18 and 25 (Period 3, Days 7 and 14)

    Time frame: Study Days 12 to 28

Secondary outcomes

  1. Assessment of safety and tolerability of sparsentan oral suspension - clinical chemistry, hematology and eGFR

    Safety laboratory tests including clinical chemistry, hematology and estimated glomerular filtration rate (eGFR) at each time point including virology and follicle stimulating hormone (FSH) (post-menopausal female subjects only) at screening

    Time frame: Study Days 1 to 28

  2. Assessment of Safety and tolerability of sparsentan oral suspension - vital sign (blood pressure)

    Supine systolic and diastolic blood pressure (BP), including change from the baseline (Day 1, Pre-dose of each study period) will be summarized (ie, n -number of subjects with an observation, mean, SD - standard deviation, median, minimum and maximum) at each post-baseline time point by regimen. The number of subjects with 'substantial' increases or decreases or no substantial change from baseline in systolic BP (\>20 mmHg), diastolic BP (\>10 mmHg) will be summarized.

    Time frame: Study Days 1 to 28

  3. Assessment of Safety and tolerability of sparsentan oral suspension - vital sign (heart rate)

    Supine heart rate, including change from the baseline (Day 1, Pre-dose of each study period) will be summarized (ie, n -number of subjects with an observation, mean, SD - standard deviation, median, minimum and maximum) at each post-baseline time point by regimen. The number of subjects with 'substantial' increases or decreases or no substantial change from baseline in heart rate (\>15 bpm) will be summarized.

    Time frame: Study Days 1 to 28

  4. Assessment of Safety and tolerability of sparsentan oral suspension - ECG

    Electrocardiogram (ECG) data, including change from baseline (Day 1, Pre-dose of each study period), will be summarized (ie, n -number of subjects with an observation, mean, SD - standard deviation, median, minimum and maximum)) at each post-baseline time point by regimen. The number and percentage of subjects with normal and prolonged QT intervals corrected for heart rate using Fridericia's correction (QTcF) and increases in QTcF intervals from baseline within the categories, defined as QTcF interval \<=450 millisecond (msec), 451-480 msec, 481-500 msec, \>500 msec, increase in QTcF interval from baseline \<30 msec, 30-60 msec, \>60 msec (based on the International Council on Harmonization \[ICH\] E14 guideline ) will be summarized at each post-baseline time point by regimen and time point.

    Time frame: Study Days 1 to 28

  5. Assessment of Safety and tolerability of sparsentan oral suspension - AEs

    An AE is any untoward medical occurrence in a subject that occurs either before dosing (referred to as a pre-dose AE) or once a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product. Treatment-emergent adverse events (TEAEs) are AEs that commence during/after the first dose of investigational medicinal product (IMP) or commence before first dose of IMP (ie, a pre-dose AE or existing medical condition) but worsen in intensity during exposure to IMP. The number and percentage of subjects reporting each TEAE will be summarized for both System Organ Class (SOC) and Preferred Term (PT). For summaries by SOC and PT, with the exception of TEAEs by severity and relationship to IMP, the number of subjects and the number of events will be summarized. For summaries by severity and relationship only the number of subjects will be summarized.

    Time frame: 2 to 28 days before Study Day 1 until 5 to 7 days post-final dose

  6. Acceptability and key taste attributes of sparsentan oral suspension

    Assess the palatability of the oral suspension using the results from a 9-point scale that rate acceptability of smell, sweetness, bitterness, flavor, mouth feel/texture, grittiness and aftertaste, and overall acceptability for a single dose of an oral suspension of sparsentan in the fasted state. Patient will rate overall liking of the product from a 9-point scale ranging from 1 = Dislike extremely and 9 = Like extremely.

    Time frame: Study Day 1

07

Study locations

1 site
  • Travere Investigational Site
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Nov 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Sep 30, 2022
StartActual
Jun 18, 2020
Primary completionActual
Nov 12, 2020
CompletionActual
Nov 12, 2020
Last update
Sep 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05562362
Lead sponsor
Travere Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Jun 18, 2020
Primary completion
Nov 12, 2020
Completion
Nov 12, 2020
Last update
Sep 30, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sparsentan

Start the discussion